|
|
|
|
| |
|
| |
|
|
| Usman,Muhammad; Zhen-Han,Zhu; Ze-Na,Chang; Jun-Ping,Han; Wen,Qian; Chang-Qing,Yang; Miyu,Nishikawa; Toshiyuki,Sakaki. |
| Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy diclofenac were assayed by high performance liquid... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Iguratimod/effects; Diclofenac/effects; 4-hydroxy diclofenac; CYP2C9/pharmacokinetics; Inhibitory. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100523 |
| |
|
|
| Hao,Dalin; Deng,Fang; Shi,Hong; Wang,Hongsheng; Xiao,Fubin; Sun,Chengxue; Xu,Yansong; Li,Peng. |
| The present study aimed to investigate the in vivo inhibitory effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) combined with sorafenib on human hepatocellular carcinoma HCCLM3 cells. The nude mice transplanted with HCCLM3 cells were randomly divided into control, SAHA, sorafenib and SAHA+sorafenib groups. The nude mice in the later 3 groups were intragastrically administrated with SAHA (10 mg·kg-1·day-1), sorafenib (10 mg·kg-1·day-1) and SAHA (10 mg·kg-1·day-1) combined with sorafenib (10 mg·kg-1·day-1), respectively, for successive 20 days. Finally, the inhibition rate of tumor was measured. The expressions of MEK1/2, p-ERK1/2, Cyclin D1, Bcl-2, Bax, p53, MMP-2, MMP-9 and uPA in tumor tissues were determined. Results showed... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Suberoylanilide hydroxamic acid; HCCLM3; Inhibitory; In vivo. |
| Ano: 2020 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100528 |
| |
|
|
|
